Objective: To explore whether ocular vestibular evoked myogenic potentials (oVEMP) can be used to detect a decrement in the extraocular muscle activity of patients with myasthenia gravis (MG).
extraocular muscle activity in MG. oVEMP is a recently developed test that records EMG activity of the inferior oblique muscle (IO). [9] [10] [11] [12] [13] Originally, the test was designed to assess otolith function. 14, 15 Here, we set out to demonstrate the utility of oVEMP to detect the decrement in extraocular muscle surface EMG of patients with MG. Compared to other tests, oVEMP would be a unique tool in ocular MG, as it may directly and noninvasively reveal the pathognomonic fatigability of extraocular muscles.
METHODS Standard protocol approvals, registrations, and patient consents. This prospective study was conducted at the Departments of Ophthalmology and Neurology, University Hospital Zurich, Switzerland. The Canton Zurich Ethics Committee approved the protocol (KEK-ZH-Nr 2010-0177). We obtained informed written consent from all participants and an authorization for disclosure for the figure and video from all recognizable participants in accordance with the Helsinki Declaration. The primary purpose of the study was to provide Class III evidence that oVEMP accurately differentiates between patients with MG with ocular symptoms and healthy controls.
Participants. We included 27 patients with MG (mean age 58 years, range 26-86 years) with ocular involvement (table e-1 on the Neurology ® Web site at Neurology.org). All patients had ocular symptoms, including ptosis (100%) and diplopia (85%). Thirteen patients (48%) had isolated ocular MG and 14 patients (52%) generalized MG. Diagnosis of MG was made based on the presence of a typical history and at least one positive ancillary test, including edrophonium testing, RNS, and serum autoantibodies (anti-acetylcholine receptor [AChR], anti-Titin, anti-MuSK). We included a control group of 28 healthy participants (mean age 47 years, range 21-86 years) without any neuromuscular, vestibular, or oculomotor disorders. All patients but one were already on pyridostigmine treatment, which was interrupted overnight in 21 patients and 4-5 hours prior to testing in 5 patients. We did not include participants with known vestibulocochlear disorders, as oVEMP signals may not be elicited in these patients. The oVEMP results of 3 healthy controls and one patient were not analyzable due to excessive blink artifacts and were excluded.
Equipment. Participants lay supine with their head on a pillow.
The skin was cleaned with abrasive gel (Nuprep; Weaver and Company, Aurora, CO) before surface electrodes (Blue Sensor N; Ambu, Ballerup, Denmark) were applied beneath the eyes. For each eye, an active electrode was placed over the infraorbital margin and a reference directly below on the cheek (figure 1). We placed a ground electrode on the chin. oVEMPs were elicited by bursts of bone-conducted skull vibration delivered with a handheld mini-shaker positioned over the hairline (mini-shaker 4810, amplifier 2706; Bruel and Kjaer, Naerum, Denmark) (video). Stimulus generation and surface EMG recording was done with laboratory data acquisition devices (power 1401, 1902 preamplifier; CED, Cambridge, UK). Signals were bandpass filtered (5-2,000 Hz) and sampled at 10 kHz with sweep-based recording software (Signal, version 5; CED). To reduce possible electromagnetic interference with the recordings, the mini-shaker was shielded with a m-Metal encasement (figure 1).
Recording. We delivered 4-ms bursts of 500-Hz boneconducted vibration in trains of 10 stimuli (video). The 10 stimuli were given at 3 different repetition rates of 3, 10, and 20 Hz. We usually started with the 3-Hz paradigm and ended with the 20-Hz paradigm. To avoid fatigue during the test, we ensured that the patients had breaks of at least 2 minutes between tests. For each paradigm, we delivered 20-30 repetitions of trains with 10 stimuli while the participants were looking up. Trains were separated by 5 seconds of rest, during which participants closed their eyes for 3 seconds.
The oVEMP signal consists of at least 2 peak-trough sequences (figure 2). The first peak-trough (n10-p15) is a vestibulardependent reflex of the IO originating from the contralateral ear. 9 The second peak-trough is also predominantly vestibular, but probably originates from both ears.
Data processing and statistics. The study results are reported in accordance with the Standards for Reporting of Diagnostic Accuracy Studies (figure e-1). Analysis of oVEMP data was performed using MatLab (MathWorks, Natick, MA). Residual main artifacts were removed using a 50-Hz notch filter (Q factor 5 10), occasional electro-oculographic eye movement artifacts after the first trial were removed using a 4th-order Butterworth Experimental setup for ocular vestibular evoked myogenic potentials recording
Recording is performed in sustained upgaze as in the Simpson test, thus activating the superior rectus and inferior oblique muscles in both eyes. A mini-shaker at the hairline of the forehead delivers the bone-conducted vibration stimulus. Active (black) and reference (red) electrodes measure the surface EMG signal from the inferior oblique muscles; ground electrode (green) is on the chin.
high-pass filter with a 20-Hz cutoff frequency. Minimal distortion of the filtered oVEMP signal was ensured by comparison to the raw signal. Signal repetitions were averaged after outliers were removed with a median absolute deviation algorithm, complemented by visual inspection. Mean rejection rates in patients and controls were similar (18 6 14% vs 15 6 11%). Statistical analyses were performed using IBM SPSS (Chicago, IL) version 22.0. Group data were described by means and SDs, unless otherwise specified. For average comparison of normally distributed data, we used unpaired Student t tests. To compare mean decrements between more affected and less affected eyes, we used paired t tests. 16 The x 2 test was used for nominal data. For nonparametric data, we applied the Mann-Whitney U test. We calculated Spearman rank coefficient for correlation analysis of non-normally distributed data. To determine optimal oVEMP cutoff values, we applied receiver operating characteristics (ROC). Significance was accepted at p , 0.05. antibodies were positive in 20/27 tested patients (74%), titin antibodies in 8/23 tested patients (35%), and MuSK antibodies in 1/21 tested patients (5%). Seven patients (26%) had negative results in all 3 antibody assays, with 6 of them having isolated ocular MG. Edrophonium test was positive in 16/18 patients (89%), while one patient had only subjective improvement of diplopia and one showed no improvement of diplopia. Both of these patients (11%) had isolated ocular MG. In 7 patients (26%), CT thorax revealed thymoma. All of them, and 4 patients without thymoma, underwent thymectomy (11 patients [41%]).
RESULTS Patient characteristics.
oVEMP in MG. oVEMP responses were present in all patients and controls. They consisted of a series of peaks and troughs and the second peak and trough were generally largest. Therefore we used the peakto-peak amplitude of this second biphasic wave to measure any decrement over the stimulus trains. Ocular vestibular evoked myogenic potentials (oVEMP) recordings oVEMP recordings in a myasthenic patient (A) and in a healthy control (B). The gray bars indicate the 10 stimuli at 20-Hz repetition rate, which are followed by characteristic oVEMP signals. OVEMP signals are averaged from 20-30 responses. The magnitude of each oVEMP signal was calculated as the sum of the second peak and second trough (asterisks). The magnitude of the decrement (C) was calculated as the difference between the amplitude of the second stimulation and the mean amplitude of the fifth to ninth stimulations. Figure 2 illustrates oVEMP recordings from a patient with MG and a healthy control explaining the decrement calculation method. We defined the decrement as the difference between the second oVEMP response and the average of the fifth to ninth responses. The first oVEMP response showed an increased amplitude with high variability in healthy controls. Therefore we used the second response as reference. Next we explored which repetition rate was best to discern patients from controls (figure 3 Using ROC analysis, we identified optimal decrement cutoffs for distinguishing patients from healthy controls (figure 4). To account for the fact that each participant contributed 2 measurements (one for each eye), 16 we explored 2 different decrement types: unilateral decrement (where at least 1 of the 2 eyes showed a decrement) and bilateral decrement (where Figure 3 Group comparison between patients with myasthenia gravis (MG) and healthy controls at 3 different repetition rates
The mean ocular vestibular evoked myogenic potentials (oVEMP) responses of the first 9 stimulations are shown for each paradigm. Each oVEMP response is indicated as normalized value 61 SD with respect to the second stimulation as reference. Mean decrement was similar in MG patients (red) and healthy controls (blue) when applying trains of 3 Hz (A) and 10 Hz (B). Only repetitive stimulation at 20 Hz (C) allowed reliable group differentiation, as indicated by the significantly larger decrement in patients with MG than in healthy controls (asterisk: p , 0.001).
both eyes showed a decrement). For the unilateral analysis, only the eye with the larger decrement was considered. For the bilateral analysis, only the eye with the smaller decrement was considered, as this eye sets the threshold for bilateral involvement. Stimulation at 20 Hz had superior diagnostic yields than 3 Hz and 10 Hz. ROC analysis revealed that in 20-Hz trains a unilateral decrement of $15.2% had a sensitivity of 89% and a specificity of 64% (24 patients and 10 controls with unilateral decrement $15.2%, p , 0.001). Instead, when using a bilateral decrement of $20.4% as cutoff, specificity was 100% and sensitivity 63% (17 patients with bilateral decrement $20.4% and 0 controls, p , 0.001). There was no correlation between the magnitude of decrement and age, and mean age was similar in patients with and without bilateral decrement (59 6 17 vs 55 6 17, p 5 0.49). 4% showed a sensitivity of 62% in ocular and 64% in generalized MG. We demonstrated the diagnostic utility of oVEMP in MG with ocular involvement. The oVEMP has only recently been introduced into clinical practice to test otolith function in vestibular disorders. The test is based on the vestibuloocular reflex and allows examination of brisk extraocular muscle activation after vestibular otolith stimulation. 11, 13, 14 All extraocular muscles probably receive neural projections from the otoliths. However, using simultaneous surface and needle recordings of the IO, we recently identified the IO as the principal origin of the excitatory potentials measured by the surface recordings in the clinical oVEMP. 9 Any structural lesion between otoliths and extraocular muscles likely affects oVEMP characteristics. Clinical application has produced 2 types of pathologic oVEMP results: (1) the amplitude of potentials may be reduced or absent, as in acute vestibular neuritis 18 ; or (2) the dynamics of potentials may be delayed as in inflammatory or neurodegenerative CNS conditions (multiple sclerosis or Parkinson disease). 19, 20 The present study, however, demonstrates a third electrophysiologic dimension of oVEMPs, namely the capability of measuring the pathognomonic decrement in extraocular muscles of patients with MG.
Using ROC analysis, we found that repetitive stimulation with 20-Hz trains provided higher discriminatory power than lower repetition rates (3-Hz and 10-Hz trains). The possibility to apply fast repetition rates is one important advantage of oVEMP, which is not possible by measuring voluntary saccadic eye movements. 21, 22 As a consequence, oVEMP allowed us to unmask myasthenic decrements even in clinically asymptomatic eyes. We defined the oVEMP decrement as the reduction between the second stimulus and the average of the fifth to ninth stimuli. For reasons to be investigated, the first stimulation produced an increased amplitude with high variability in healthy controls, while the second response was sometimes larger than the first at high repetition rate in patients with MG. Superimposition of subtle blink artifacts may in part account for this effect, although analysis of all patients' and controls' curves demonstrated such effects also in the absence of obvious blink artifacts. The fluctuations observed during the first 2 stimuli may reflect facilitation effects, possibly caused by acetylcholine quantal release. 23 For these reasons, we preferred to use the second peak as a reference value to avoid any bias by differently enlarged first peaks. A critical question concerns the differential discriminatory power of a unilateral vs bilateral decrement. The advantage of unilateral decrement is gain in sensitivity, which may be particularly desirable when evaluating patients with mild symptoms. On the other hand, the advantage of using a bilateral decrement is its high specificity, which is on a par with the 94%-99% specificity described for other methods including antibody assays and RNS. 24 The cause of occasional unilateral decrements in controls remains unclear, but artifacts due to positioning of the mini-shaker should be considered. Little is known about the variability in disease severity between individual extraocular muscles, but our oVEMP measurements may have failed to detect a decrement if the myasthenic process spared the IO. Thus, technical improvements enabling recordings from additional extraocular muscles may improve oVEMP sensitivity in ocular MG even further.
Compared to other diagnostic tests for MG, oVEMP has several merits. Antibody assays and RNS are highly specific, but have low sensitivities in ocular MG. For instance, an overview of 6 studies assessing the diagnostic accuracy of anti-AChR antibodies found sensitivities of 87%-98% in generalized MG but only 39%-71% in ocular MG. 24 Similarly, 6 of our patients with ocular MG were tripleseronegative, including 3 patients with no decrement in RNS, yet 5 of them had positive oVEMP results, thus highlighting the diagnostic usefulness of oVEMP in this challenging subgroup.
The sensitivity of RNS in ocular MG is even lower, ranging between 11% and 39%. 24 In ocular MG, SFEMG is considered the diagnostic gold standard, as reflected by 4 studies reporting a high sensitivity of 92%-97%, 8, [25] [26] [27] although 2 other groups found lower sensitivities of 83% and 62%. 28, 29 Comparison of different EMG tests in ocular MG demonstrated that the closer the measurement to the extraocular muscles, the higher the sensitivity. In contrast to SFEMG, oVEMP not only directly assesses the extraocular muscles, but is also better tolerated, because it is less invasive, less cumbersome, and less operator-dependent.
oVEMP also has several advantages over the edrophonium test. Edrophonium testing is limited to patients with observable deficits (e.g., ptosis, diplopia) and is contraindicated in cardiac or respiratory disease. In addition, the drug is not registered in many countries and therefore often unavailable outside university hospitals.
Our study suggests that oVEMP bypasses many of the abovementioned limitations, as its diagnostic sensitivity seems less susceptible to immunologic and clinical heterogeneity in MG. In other words, oVEMP gives direct evidence of the myasthenic decrement in affected extraocular muscles, irrespective of the exact underlying immunologic process. Therefore, oVEMP is suitable to become an integral diagnostic part of the routine evaluation of patients with suspected MG.
Since the main purpose of the study was proof of principle, we used a case-control and not a cohort study design. In other words, we provide Class III evidence of the capability of oVEMP to distinguish between patients with MG and healthy controls, but future studies will need to confirm its diagnostic utility in clinical practice, when the main challenge is differentiation from patients with other neuroophthalmologic conditions. Second, we studied patients with previously established diagnoses because we wanted to validate our oVEMP measurements in MG. A consequence was that all patients but one were already under treatment with cholinesterase inhibitors, although oVEMP was usually performed in the morning prior to the first drug intake of the day. Therefore it remains unclear what the diagnostic accuracy of oVEMP would be in drug-naive patients, though it can be speculated that more pronounced muscle fatigability would actually enhance the sensitivity of oVEMP, similar to the treatment effects on RNS in generalized MG. 30, 31 Third, ophthalmoparesis was mild in our patients and it remains to be determined to what extent severe limitation in upward gaze may interfere with oVEMP testing. Fourth, we did not randomize the sequence of the tests, but performed the 3-Hz test first, and the 20-Hz test at the end. Nevertheless, the tests were short and patients had breaks between the tests, so that a potential sequence-induced bias due to a cumulative fatigue effect should be minimal. Finally, our control group was slightly younger, and small age-related effects on oVEMP have been described. 32, 33 Nevertheless, we did not find any correlation between the magnitude of decrement and age, and mean age was similar in patients with and without bilateral decrement.
Our findings indicate that oVEMP has the potential to play a helpful role in the diagnosis of ocular MG. Compared to other diagnostic procedures, oVEMP has the unique advantage of providing direct evidence of the myasthenic process in affected extraocular muscles. Technical advances and optimization in signal detection from as many different extraocular muscles as possible will likely further increase the sensitivity of oVEMP in MG. Finally, oVEMP is a simple, noninvasive, and fairly inexpensive tool that can be linked to any standard EMG equipment and therefore easily implemented in any clinical electrophysiology unit.
